MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma

• Lucia Y. Chen,
• Santiago Thibaud,
• Saoirse Bodnar,
• Ajai Chari,
• Joshua Richter,
• Hearn Jay Cho,
• Larysa J. Sanchez,
• Cesar Rodriguez,
• Adriana C. Rossi,
• Shambavi Richard,
• Samir Parekh,
• Sundar Jagannath

Affiliations

Lucia Y. Chen

Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, Oxford University, Oxford, United Kingdom

Santiago Thibaud

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Saoirse Bodnar

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Ajai Chari

Division of Hematology/Oncology, University of California San Francisco, San Francisco, CA

Joshua Richter

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Hearn Jay Cho

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Larysa J. Sanchez

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Cesar Rodriguez

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Adriana C. Rossi

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Shambavi Richard

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Samir Parekh

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY

Sundar Jagannath

Division of Hematology/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY; Correspondence: Sundar Jagannath, The Tisch Cancer Institute, 1 Gustave L Levy Place, Box 1185, New York, NY 10029;